[Value of determining prostate-specific antigen for early detection or prostatic carcinoma]

Urologe A. 1995 Jul;34(4):283-9.
[Article in German]

Abstract

The use of prostate-specific-antigen in the early detection of prostatic carcinoma combined with digital-rectal examination results in a 2-3 times increase in prostatic carcinoma detection rate. 2/3 of PSA detected prostatic carcinoma are organ confined vs 40% of those which are detected by digital-rectal examination. 15-35% of all operated localized prostatic carcinoma have a normal PSA. A biopsy is indicated in men with a life expectancy of more than 10 years when the PSA value is above 10 ng/ml and/or digital-rectal examination is suspicious. This concerns only 2% of all men at the age older than 50 years. In 90% of all men older than 50 years the PSA is normal as well as the digital-rectal examination. In 4% of these the result of PSA and digital-rectal examination is false negative that means 4% have prostatic carcinoma. However, repeated digital-rectal examination and PSA determination on a yearly basis detects most of these overlooked prostatic carcinoma which still are organ confined in about 90% of the cases. In men with a minimal elevated PSA-value of 4-10 ng/ml, 25% will have a prostatic carcinoma regardless of the finding on digital-rectal examination. The indication to do a biopsy can be specified by the use of age specific PSA cut-off-levels and most likely in future by determining the free PSA vs the complex-bound PSA. Controversy exists about the usefulness of PSA-density and PSA-velocity.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood*
  • Humans
  • Male
  • Mass Screening*
  • Middle Aged
  • Neoplasm Staging
  • Palpation
  • Prognosis
  • Prostate / pathology
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / enzymology
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / prevention & control*
  • Reference Values

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen